International Journal of Medical and Pharmaceutical Research
2023, Volume-4, Issue-3 doi: 10.5281/zenodo.8076624
Original Article
Outcome of HFNC Oxygen Therapy in Infants and Children Presenting in PICU with Acute Respiratory Distress
 ,
 ,
 ,
Published
June 24, 2023
Abstract
High flow nasal cannula is an emerging treatment option in paediatric intensive care units for paediatric patients In acute respiratory distress. Yet there is a paucity of literature describing its clinical application in various presenting pathophysiology. It can avoid invasive method of mechanical ventilation and offers a safe practical approach to oxygen delivery and support. Aim is to describe 9 cases with acute respiratory distress with differing underlying pathophysiology and their response to high flow nasal Cannula oxygen therapy. Patients admitted in PICU with acute respiratory distress with acute encephalitis, congenital heart disease, laryngomalacia etc and treated with HFNC oxygen therapy were chosen to review. 4 infants and 6 children were reviewed. All were commenced on high flow nasal cannula therapy in PICU and all demonstrated an improvement in their work of breathing. 2 patients were referred to higher Centre in view of CHD with improvement on HFNO. There was also a substantial improvement in their haemodynamic status. HFNO Therapy is an viable treatment option for a range of patients presenting to PICU With acute respiratory distress. More invasive method of respiratory support may be avoided by use of HFNC oxygen therapy.
Recommended Articles
Loading Image...
Volume-4, Issue-3
Citations
1774 Views
346 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved